Israel study of Pfizer vaccine shows 94% decrease in symptomatic COVID-19 cases

A recent study by Israel’s largest healthcare provider showed that after both doses of the Pfizer vaccine, people are 94% less likely to have symptomatic COVID-19 infections and 92% fewer cases of serious illness due to the virus, Reuters reports.

Why it matters: Israel has rapidly vaccinated its population, and the new study underscores how effective the vaccine is, as the data are almost similar to Pfizer’s Phase Three clinical trials, which showed that the vaccine was 95% effective.

Stay up to date with the latest market trends and financial insights with Axios Markets. Subscribe for free

Where it says: According to Reuters, Clalit, the health system that covers most Israelis, compared 600,000 people who received both doses of the Pfizer vaccine against a group of the same size with matching medical histories who had not yet received the vaccine.

  • Researchers at the Weizmann Institute of Science reported a decline in hospitalization and serious illness in people aged 55 and over.

  • “It shows unequivocally that Pfizer’s coronavirus vaccine is extremely effective in the real world one week after the second dose, just as it turned out in the clinical study,” said Ran Balicer, Clalit’s Chief Innovation Officer.

  • The data also indicate that the Pfizer vaccine is “even more effective two weeks or more after the second shot”.

Do you like this article? Get more out of Axios and subscribe for free at Axios Markets.

Spread the love
[ Sharing is Caring! ]

More Tags We Love

what do you do if you lost your social insurance card how do i qualify for unemployment insurance benefits state minimum auto insurance coverage how to find the cheapest auto insurance auto insurance under 100 a month insurance cost new driver average auto insurance cost california best insurance rates in co auto insurance best rates car insurance for over 60s

This div height required for enabling the sticky sidebar